CN1412189A - Method for synthesizing 3 (or8)-(1-methoxyethyl)-8-(or3)-(1-hydroxyethyl)-deuteroporphyrin IX - Google Patents
Method for synthesizing 3 (or8)-(1-methoxyethyl)-8-(or3)-(1-hydroxyethyl)-deuteroporphyrin IX Download PDFInfo
- Publication number
- CN1412189A CN1412189A CN 01131939 CN01131939A CN1412189A CN 1412189 A CN1412189 A CN 1412189A CN 01131939 CN01131939 CN 01131939 CN 01131939 A CN01131939 A CN 01131939A CN 1412189 A CN1412189 A CN 1412189A
- Authority
- CN
- China
- Prior art keywords
- deuteroporphyrin
- hydroxyethyl
- ethyl
- reaction
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention provides two method for synthesizing 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1- ethoxyl)-deuteroporphyrin IX by using 3,8-bis (1-bromoethyl)-deuteroporphyrin IX dihydrobromate as initiation material. One method includes hydrolysis of initiation material, esterification and alkoxy cracking; and second method includes the processes of using methyl alcohol to etherifying initiation material, then using hydrochloric acid to remove methylation. The product is undergone the chromatographic separation treatment so as to obtain the invented pure product.
Description
Technical field
The invention belongs to the pharmaceutical chemistry field, be specifically related to the synthetic method of 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX.
Background technology
Present inventors etc. delivered the synthetic first interim report (Zhang Hao about 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX (popular name is 3-or 8-hematoporphyrin monomethyl ether) in 1989, Xu Deyu: the synthetic and tumour photo bio activity research of semi-synthetic hematoporphyrin derivative, Chinese Journal of Pharmaceuticals 1989,20: 60), reported the photodynamic killing effect [Xu Deyu of 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX again to animal-transplanted tumor and vitro culture human cancer cell thereupon, Chen Wenhui, Shen Nianci: light power cancer curing medicine 3-or 8-hematoporphyrin monomethyl ether, Chinese laser medical journal 1993,2:1; J.Military Med.College 1991,8:406].
Preliminary proof such as Gu Ying, 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX has reliable clinical efficacy (Gu Ying, Li Junheng, Xu Deyu: novel photosensitive agent---the Preliminary report of hematoporphyrin monomethyl ether clinical application to the esophageal carcinoma and cancer of the stomach etc., Chinese laser medical journal 1993,2:235; Gu Yin, Li Jun-Heng, Xu De-Yu:A preliminary report of clinicalapplication of hematoporphyrin monomethyl ether in photodynamic therapyfor alimentary cancers.SPIE 1994, Vol.2371:385).
Chinese People's Liberation Army General Hospital's laser section used 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX laser power therapeutic nevus flammeus in recent years, (Gu Ying: hematoporphyrin monomethyl ether is used for the synthetic study of novel photodynamic therapy treatment nevus flammeus to have obtained good effect, the doctorate paper, in May, 2000; Chinese laser medical journal 1993,2:154; 1994,3:215).
These studies show that, 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX is a kind of effective novel optical dynamic therapy medicine, as single compound, it has overcome mixing porphyrin preparation phytochrome II or non-nurse sodium (the Photofrin II of porphin that present home and abroad is used for clinical optical dynamic therapy first, Sodium Pofimer) and hematoporphyrin derivative (HematoporphyrrinDerivative is HpD) because of forming the unstable and standardized shortcoming of difficult quality of the not clear curative effect that is caused of indefinite and effective constituent own.
Basis and clinical study show that all 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX is a kind of tumour and nevus flammeus optical dynamic therapy new drug that good development prospect is arranged.The present inventor concentrates on studies for many years for the synthetic method of this optical dynamic therapy new drug, has applied for patent of invention (CNO110528.2) January 11 calendar year 2001.This application for a patent for invention relates to the ferric sesquichloride protoporphyrin and reaction of hydrogen bromide generates 3,8-two (1-bromotrifluoromethane)-deuteroporphyrin IX two hydrobromates, the latter and the reaction of methanol mixed solution generate 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX.
Summary of the invention
The object of the present invention is to provide with 3,8-two (1-bromotrifluoromethane)-deuteroporphyrin IX two hydrobromates are the novel method of two kinds of synthetic 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-the hydroxyethyl)-deuteroporphyrin IX of initial substance.
First kind of synthetic method of formula provided by the invention (I) compound
Wherein, R is 1-methoxy ethyl or 1-hydroxyethyl, it is characterized in that may further comprise the steps:
(1) 3,8-two (1-bromotrifluoromethane)-saturated glacial acetic acid solution of deuteroporphyrin IX two hydrobromates and water reaction generate 3,8-two (1-hydroxyethyl)-deuteroporphyrin IX;
(2) 3,8-two (1-hydroxyethyl)-deuteroporphyrin IX and the reaction of the vitriol oil-acetic acid (1: 19) mixed solution, generate 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX and 3,8-two-(oxygen ethanoyl ethyl)-deuteroporphyrin IX mixture obtains 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX through chromatographic separation;
(3) 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX reflux in methyl alcohol, production (I) compound.
Second kind of synthetic method of compound shown in the formula provided by the invention (I)
In the formula, R is 1-methoxy ethyl or 1-hydroxyethyl, it is characterized in that may further comprise the steps:
(1) 3,8-two (1-bromotrifluoromethane)-saturated glacial acetic acid solution of deuteroporphyrin IX two hydrobromates and excessive methanol reflux obtains 3,8-two-(methoxy ethyl)-deuteroporphyrin IX;
(2) 3,8-two-(methoxy ethyl)-deuteroporphyrin IX and hydrochloric acid reaction, product separate formula (I) compound.
Specific embodiments
The method of compound all adopts 3 shown in two kinds of synthesis types of the present invention (I), and 8-two (1-bromotrifluoromethane)-deuteroporphyrin IX is as initial substance.
First kind of synthetic method undertaken by following flow process 1: flow process 1
The step of flow process 1 (1) is with 3, and 8-two (1-bromotrifluoromethane)-0 ℃ of following and water reaction of the saturated glacial acetic acid solution of deuteroporphyrin IX two hydrobromates generates 3,8-two (1-hydroxyethyl)-deuteroporphyrin IX (also being called haematoporphyrin IX).In this step, temperature of reaction is controlled at below 0 ℃, and the by product of reaction is reduced; The volume of water is preferably 3, and the 3-5 of 8-two (1-bromotrifluoromethane)-saturated glacial acetic acid solution volume of deuteroporphyrin IX two hydrobromates doubly can make reaction carry out more fully.
Step (2) is with 3; generate 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX and 3 with the vitriol oil-acetic acid (1: 19) mixed solution stirring reaction under 8-two (1-hydroxyethyl)-deuteroporphyrin IX (haematoporphyrin IX) room temperature; 8-two-(oxygen ethanoyl ethyl)-deuteroporphyrin IX mixture obtains 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-pure product of (1-hydroxyethyl)-deuteroporphyrin IX through chromatographic separation.In this step, the ratio of the haematoporphyrin and the vitriol oil-acetic acid mixed solution is 1: 20 (W/V), reaction times visual response scale and deciding, and available thin-layer chromatography detects, and is the best terminal point of reaction with the single acetyl thing that generates during with diacetyl thing ratio maximum.
Step (3) is that 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX reflux in methyl alcohol is carried out the alcoxyl scission reaction, generates 3-(or 8)-(methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX.Used methyl alcohol should be the analytical pure anhydrous methanol in this step.Carry out for guaranteeing to be reflected under the non-water state, the prolong outlet of reflux connects the Calcium Chloride Powder Anhydrous drying tube.Detect the performance level of alcoxyl scission reaction in the reaction process with thin-layer chromatography, make unreacted residual thing amount reach inferior limit as far as possible.
Second kind of synthetic method of the present invention undertaken by following flow process 2:
Flow process 2
The step of flow process 2 (1) is with 3, and 8-two (1-bromotrifluoromethane)-saturated glacial acetic acid solution of deuteroporphyrin IX two hydrobromates and excessive methanol reflux obtains 3,8-two-(methoxy ethyl)-deuteroporphyrin IX.
Step (2) is with 3,8-two-(methoxy ethyl)-deuteroporphyrin IX and hydrochloric acid stirring reaction generate 3-(or 8)-(methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX and haematoporphyrin IX mixture, and chromatographic separation gets pure 3-(or 8)-(methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX.
In the method for the invention, the chromatographic separation of product adopts silicagel column, and developping agent is methyl alcohol-chloroform-formic acid 10: 1: 0.1 (V/V); Or ethyl acetate-acetone-Glacial acetic acid 7: 3: 0.1 (V/V); Or chloroform-methanol-acetone-formic acid 10: 1: 1: 0.1 (V/V).Be preferably methyl alcohol-chloroform-formic acid 10: 1: 0.1 (V/V).Detect and adopt silica gel tlc and HPLC (Whatman ODS post).The solvent system of silica gel tlc separates with the post layer.The moving phase of HPLC is tetrahydrofuran aqueous solution and sodium-acetate buffer.
The technological operation of the inventive method is easy, the reaction raw materials cheapness, is easy to get, and equipment is simple, both has been suitable for the laboratory and has used on a small scale, also is suitable for industrial production.
Below with embodiment the present invention is illustrated, these embodiment are intended to set forth optimum implementation of the present invention.Those skilled in the art are according to enlightenment of the present invention, and the various changes in conjunction with the general knowledge of this area is done all drop in the scope of the application's claim.
Embodiment 13, the preparation of 8-two-(1-hydroxyethyl)-deuteroporphyrin IX
According to plan resultant quantity needs, get 3 of respective amount, 8-two (1-bromotrifluoromethane)-deuteroporphyrin IX two hydrobromate Glacial acetic acid saturated solutions, place dropping funnel, stir down and drip in the distilled water of 5-10 times of volume of its weight in 0 ℃, after finishing, placed 1 hour, and slowly added the 10N sodium hydroxide solution in the reaction mixture and be neutralized to pH 7-8, N-process maintenance temperature of reaction on the rocks is no more than 0 ℃, add acetum, regulate pH to 4-5, placed 1-2 hour, the red-purple 3 that the filter collection is separated out, 8-two-(1-hydroxyethyl)-deuteroporphyrin IX throw out, drying under reduced pressure.
The preparation of embodiment 2 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX
Get above-mentioned make 3; 8-two-(1-hydroxyethyl)-deuteroporphyrin IX 100g; by 1: 20w/v ratio and 1: 19 vitriol oil-acetic acid mixed solution (2000mL) stirring reaction under room temperature; thin-layer chromatography detection reaction resultant 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX and 3; the ratio of 8-two-(oxygen ethanoyl ethyl)-deuteroporphyrin IX, with 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-when deuteroporphyrin IX growing amount reaches maximum as reaction end.Reaction mixture is neutralized to pH4-5 with the saturated acetic acid sodium solution under room temperature; suction strainer is collected the red-purple throw out of separating out; behind the drying under reduced pressure; the silica gel column chromatography separation obtains 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX and 3, the 8-two-pure product 56g of (oxygen ethanoyl ethyl)-deuteroporphyrin IX.
The preparation of embodiment 3 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX
Get the above-mentioned 3-that makes (or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX50g and place a 250mL three neck round-bottomed flasks, add absolute anhydrous methanol 100-150mL, heated and stirred refluxes in water-bath, notices that condensator outlet should connect the Calcium Chloride Powder Anhydrous drying tube.Thin-layer chromatography detects the performance level of alcoxyl scission reaction; stopped reaction when treating that 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX almost completely changes 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX into; reclaim methyl alcohol in the decompression rotatory evaporator, the gained remnant is target compound 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX.As find that small amount of impurities is arranged in the finished product, can borrow column chromatography separating purification it, dry pure 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX 41-45g.
Embodiment 43, the preparation of 8-two-(1-methoxy ethyl)-deuteroporphyrin IX
According to plan preparation amount needs, get 3 of respective amount, 8-two (1-bromotrifluoromethane)-deuteroporphyrin IX two hydrobromate Glacial acetic acid saturated solutions, decompression extracts acetic acid and excessive hydrogen bromide, add a large amount of anhydrous diethyl ethers or acetone in the raffinate, suction strainer collect separate out 3,8-two (1-bromotrifluoromethane)-deuteroporphyrin IX two hydrobromate solids, and with a small amount of anhydrous propanone drip washing 2-3 time puts after decompression/P205 drains in the vacuum drier, get 150g3,8-two (1-bromotrifluoromethane)-deuteroporphyrin IX two hydrobromate solids place 500mL three neck round-bottomed flasks, add methyl alcohol 250-300mL, and heated and stirred refluxes, reaction solution borrows thin-layer chromatography to detect frequently, finishes until etherificate.The reaction solution heating recovery methyl alcohol that in rotatory evaporator, reduces pressure, garnet 3,8-two-(1-methoxy ethyl)-deuteroporphyrin IX solid 86-98g.
The preparation of embodiment 5 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX with separate
Get above-mentioned 3,8-two-(1-methoxy ethyl)-deuteroporphyrin IX is dry, and pure product 50g places a 250mL round bottom three-necked bottle, add 6N hydrochloric acid 100-150mL, under the room temperature stirring reaction 10-12 hour, reaction solution adds the saturated acetic acid sodium solution and is neutralized to pH4-5, suction strainer is collected 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-the hydroxyethyl)-deuteroporphyrin IX that separates out, 3,8-two-(1-hydroxyethyl)-deuteroporphyrin IX and unreacted raw mix red-purple precipitation, behind the drying under reduced pressure, silica gel column chromatography separate 2g 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-pure product 28-31g of (1-hydroxyethyl)-deuteroporphyrin IX.
The chromatographic separation and the detection of embodiment 6 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-(1-hydroxyethyl)-pure product of deuteroporphyrin IX
Chromatographic separation condition:
Chromatographic column: 60-120 * 800-1500mm is suitable for reading to be the Glass tubing of 24-34 standard ground, outflow end band 3# acid-resistant glass filter plate;
Balustrade: 200-300 order chromatographic silica gel;
Developping agent: methyl alcohol-chloroform-formic acid (10: 1: 0.1 V/V);
Temperature: room temperature (comprising the four seasons)
Flow velocity: 6-8ml/ minute
Applied sample amount: applied sample amount: silica gel=2-4: 100 (W/W);
Operation steps: silica gel H 200g borrows long neck funnel slowly to fill in 60 * 600mm chromatography column, strike reality.Get and be laid on the silicagel column upper strata after blood quinoline methyl ether .5～6g and 25g silica gel H grind well, and layer adds silica gel sheet 0-25g in addition thereon, ditto strikes reality.The glass-tube of borrowing the standard mouth to connect one 20 * 800mm suitable for reading at post, the plastics tubing of borrowing the 2-3mm diameter by reservoir with developping agent through on connect glass-tube and flow into chromatographic column, after treating that the solvent leading edge is flow to end, Fractional Collections is by the effusive red stream part of chromatographic column, and detect with thin plate at any time, when effluent liquid TCL detects the single spot be for Rf value 0.58-0.71, carry out the HPLC analysis immediately.Leave and take and merge TCL and be detected on the flow point that the single spot of Rf value 0.58-0.71, HPLC are analyzed 7.08 minutes relative peak area of retention time 〉=98%, evaporated under reduced pressure promptly gets 3-(or 8)-(1-methoxy ethyl)-8-(or 3)-pure product of (1-hydroxyethyl)-deuteroporphyrin IX.
Repeat to test several times, obtaining pure product amount is 1.5-2.2g (yield 30-36%), and purity is more than or equal to 95%.
Change developping agent into ethyl acetate-acetone-Glacial acetic acid (7: 3: 0.1 V/V), all the other operations are the same, repeat to test several times, and obtaining pure product amount is 1.45-2.0g (yield 24-33%), and purity is more than or equal to 95%.
(10: 1: 1: 0.1 V/V), all the other operations were the same, repeat to test several times, and obtaining pure product amount is 1.35-1.75g (yield 22.5-29%), and purity is more than or equal to 95% to change developping agent into chloroform-methanol-acetone-formic acid.
Examination criteria: TCL analyzes in conjunction with HPLC, and condition is respectively:
TCL detects:
Condition:
The preparation of silica-gel plate (1) silica gel G plate: 40g chromatographic silica gel G (Haiyang Chemical Plant, Qingdao's production) adds 0.3% carboxymethyl cellulose (CMC) solution 100ml, stirs evenly the back and makes the thick chromatoplate of 0.25mm on the slide glass upper berth.Activate 1 hour in 100-110 ℃ after latter's seasoning.(2) silica gel H plate: 33g chromatographic silica gel H (Haiyang Chemical Plant, Qingdao's production) adds 0.6%CMC solution 100ml, stir evenly the back on slide glass, be paved into the thick thin plate of 0.25mm, treat seasoning after, in 100-110 ℃ the activation 1 hour.
Point sample point sample amount is 1 μ l (containing sample 2 μ g);
Solvent system and expansion mode solvent system separate with the front pillar layer, the vertical expansion;
Only present single rose spot on the examination criteria thin plate, its Rf value temperature and development distance when detecting are about 0.58-0.71;
HPLC detects:
Condition:
Separator column Whatman ODS post, 46 * 250mm;
Moving phase 60% (V/V) tetrahydrofuran aqueous solution+10%0.2mol/L sodium-acetate buffer;
20 ± 1 ℃ of column temperatures;
Flow velocity 1ml/ minute;
Post is pressed 250 crust;
Detect wavelength 395nm;
Sensitivity 0.1AUFS;
Chary speed 2mm/ minute;
Sample size 5 μ L (sample concentration is 1mg/1mL).
Claims (9)
1. the synthetic method of compound shown in the formula (I)
Wherein, R is 1-methoxy ethyl or 1-hydroxyethyl, it is characterized in that may further comprise the steps:
(1) 3,8-two (1-bromotrifluoromethane)-saturated glacial acetic acid solution of deuteroporphyrin IX two hydrobromates and water reaction generate 3,8-two (1-hydroxyethyl)-deuteroporphyrin IX;
(2) 3,8-two (1-hydroxyethyl)-deuteroporphyrin IX and the reaction of the vitriol oil-acetic acid (1: 19) mixed solution, generate 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX and 3,8-two-(oxygen ethanoyl ethyl)-deuteroporphyrin IX mixture obtains 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX through chromatographic separation;
(3) 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX reflux in methyl alcohol, production (I) compound.
2. the method for claim 1, wherein in the step (1), temperature of reaction is 0 ℃, and volume of water is 3, and the 3-5 of 8-two (1-bromotrifluoromethane)-saturated glacial acetic acid solution volume of deuteroporphyrin IX two hydrobromates is doubly.
3. the method for claim 1; wherein in the step (2) 3; the ratio of 8-two (1-hydroxyethyl)-deuteroporphyrin IX and the vitriol oil-acetic acid mixed solution is 1: 20 (w/v); reaction end is that thin-layer chromatography detects 3-(or 8)-(oxygen ethanoyl ethyl)-8-(or 3)-(1-hydroxyethyl)-deuteroporphyrin IX and 3, the time of the ratio maximum of 8-two-(oxygen ethanoyl ethyl)-deuteroporphyrin IX.
4. the method for claim 1, wherein used methyl alcohol is the analytical pure anhydrous methanol in the step (3), reaction end is that thin-layer chromatography detects the minimum time of unreacted reactant.
5. the method for claim 1, wherein chromatographic separation adopts silicagel column, and developping agent was selected from methyl alcohol-chloroform-formic acid 10: 1: 0.1V/V; Ethyl acetate-acetone-Glacial acetic acid 7: 3: 0.1V/V; Chloroform-methanol-acetone-formic acid 10: 1: 1: 0.1V/V.
6. the synthetic method of compound shown in the formula (I)
In the formula, R is 1-methoxy ethyl or 1-hydroxyethyl, it is characterized in that may further comprise the steps:
(1) 3,8-two (1-bromotrifluoromethane)-saturated glacial acetic acid solution of deuteroporphyrin IX two hydrobromates and excessive methanol reflux obtains 3,8-two-(methoxy ethyl)-deuteroporphyrin IX;
(2) 3,8-two-(methoxy ethyl)-deuteroporphyrin IX and hydrochloric acid reaction, product separate formula (I) compound.
7. method as claimed in claim 6, used methyl alcohol is the analytical pure anhydrous methanol in the wherein said step (1), return time is decided according to the thin-layer chromatography detected result.
8. method as claimed in claim 6, used concentration of hydrochloric acid is 6N in the wherein said step (2), the reaction times should decide according to the thin-layer chromatography detected result.
9. method as claimed in claim 6, wherein chromatographic separation adopts silicagel column, developping agent to be selected from methyl alcohol-chloroform-formic acid 10: 1: 0.1V/V; Ethyl acetate-acetone-Glacial acetic acid 7: 3: 0.1V/V; Chloroform-methanol-acetone-formic acid 10: 1: 1: 0.1V/V.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01131939 CN1255408C (en) | 2001-10-17 | 2001-10-17 | Method for synthesizing 3 (or8)-(1-methoxyethyl)-8-(or3)-(1-hydroxyethyl)-deuteroporphyrin IX |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01131939 CN1255408C (en) | 2001-10-17 | 2001-10-17 | Method for synthesizing 3 (or8)-(1-methoxyethyl)-8-(or3)-(1-hydroxyethyl)-deuteroporphyrin IX |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1412189A true CN1412189A (en) | 2003-04-23 |
| CN1255408C CN1255408C (en) | 2006-05-10 |
Family
ID=4670994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01131939 Expired - Lifetime CN1255408C (en) | 2001-10-17 | 2001-10-17 | Method for synthesizing 3 (or8)-(1-methoxyethyl)-8-(or3)-(1-hydroxyethyl)-deuteroporphyrin IX |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1255408C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005018634A1 (en) * | 2003-08-25 | 2005-03-03 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | The use of the hernatoporphyrin monomethyl ether for the treatment of the eye disorders |
| CN1712404B (en) * | 2004-06-15 | 2010-06-02 | 上海复旦张江生物医药股份有限公司 | Purification of porphyrin medicine |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102363619A (en) * | 2011-11-18 | 2012-02-29 | 中国医学科学院生物医学工程研究所 | Water soluble protoporphyrin compound and preparation method and use thereof |
-
2001
- 2001-10-17 CN CN 01131939 patent/CN1255408C/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005018634A1 (en) * | 2003-08-25 | 2005-03-03 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | The use of the hernatoporphyrin monomethyl ether for the treatment of the eye disorders |
| CN1712404B (en) * | 2004-06-15 | 2010-06-02 | 上海复旦张江生物医药股份有限公司 | Purification of porphyrin medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1255408C (en) | 2006-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0120054B1 (en) | Purified hematoporphyrin derivative for diagnosis and treatment of tumors, and method | |
| CN109796483B (en) | Water-soluble cationic photosensitizer and preparation and application thereof | |
| CN111087285A (en) | Method for extracting bibenzyl compounds from dendrobium officinale and application of bibenzyl compounds | |
| CN112409307B (en) | Compound Olerafuran A in purslane, and extraction and separation method and application thereof | |
| CN1101373C (en) | Novel terphenyl compounds and medicines containing the same | |
| CN101012230A (en) | Preparing process of sodium cantharidinate | |
| CN1879672A (en) | A medicament containing effective components of glabrous sarcandra herb, its preparation method and application | |
| CN1255408C (en) | Method for synthesizing 3 (or8)-(1-methoxyethyl)-8-(or3)-(1-hydroxyethyl)-deuteroporphyrin IX | |
| Chatterjee et al. | Studies on the chemical constituents of Nardostachys jatamansi DC (Valerianaceae) | |
| CN103288840B (en) | Phthalocyanine-erlotinib yoke compound and preparation and application thereof | |
| CN106967058A (en) | A kind of preparation method for Wo Zhani | |
| CN1142165C (en) | Preparation of partially synthesized deuteroporphyrin derivative and its freeze dried injection | |
| CN113797350B (en) | Glycosyl polymer and preparation method and application thereof | |
| CN107382875A (en) | A kind of synthetic method of rosuvastain calcium chiral isomer impurity | |
| CN101050214A (en) | New method for extracting Swainsonine from locoweed | |
| CN103012359B (en) | (2 ' S)-Kadsuralignan J and preparation method thereof | |
| CN1148184C (en) | Composite medicine for optical dynamic treatment of tumor | |
| CN1305870C (en) | Novel flavane derivative and its preparation method and uses | |
| HAGINAKA et al. | Epimerization of amoxicillin piperazine-2, 5-dione in acidic solutions | |
| CN111285866A (en) | Hg detection method2+/ClO-Double-channel berberine-based fluorescent probe and preparation method and application thereof | |
| JP2013103884A (en) | Industrial production method of pitavastatin calcium salt | |
| CN102993268B (en) | Preparation method of oyster shell antioxidation peptide | |
| CN1872084A (en) | Extractive of Chinese globeflower in short petal, effective content of anti inflammation and usage | |
| CN111995560B (en) | Monoterpene indole compound and preparation method and application thereof | |
| CN1712404B (en) | Purification of porphyrin medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091120 Address after: Shanghai Zhangjiang High Tech Park of Pudong New Area Cailun Road No. 308 Co-patentee after: Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd. Patentee after: Shanghai Fudan Zhangjiang biological medicine Limited by Share Ltd Address before: Shanghai Zhangjiang High Tech Park of Pudong New Area Cailun Road No. 308 Patentee before: Fudan Zhangjiang Biological Medicine Co., Ltd., Shanghai |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060510 |
|
| CX01 | Expiry of patent term |